The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as ENDEAVOR, Study 9001-103 is a multi-cohort study ...

Subungual melanoma which appears under fingernails and toenails, is a rare but serious form of skin cancer that typically isn ...

Subungual melanoma which appears under fingernails and toenails, is a rare but serious form of skin cancer that typically isn ...

Windtree Therapeutics, Inc. ("Windtree” or "the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative ...

Bayer BAYRY announced first-quarter 2025 results. Novo Nordisk NVO and GSK plc GSK announced licensing deals with smaller ...

AbbVie’s Emrelis (telisotuzumab vedotin-tllv) has been granted accelerated approval by the US Food and Drug Administration ...

Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 ...

SHELTON, CT / ACCESS Newswire / May 16, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025 ...

Jubilant Pharmova rallied 4.54% to Rs 947.05 after the company reported net profit of Rs 153.60 crore in Q4 FY25 compared with net loss of Rs 58.60 crore in Q4 FY24.

The Chief Executive Officer (CEO) of the FDA, Dr Delese A. A. Darko, has called for clear, ethical and enforceable ...